VISEN PHARMA-B (VISEN Pharmaceuticals) disclosed a share buyback executed on 26 May 2026 under its Hong Kong Exchange mandate.

On-market repurchase details • Volume: 10,200 ordinary shares • Price range: HKD 22.66–23.48 per share • Volume-weighted average price (per Section I): HKD 22.86 • Aggregate consideration: HKD 0.23 million

Capital structure after the transaction • Issued shares (excluding treasury shares) decreased to 113.88 million. • Treasury shares rose to 43,400, leaving total issued shares unchanged at 113.93 million. • The shares repurchased represent approximately 0.009 % of the company’s issued share capital prior to the transaction.

Repurchase mandate status • Mandate granted on 27 June 2025 authorises buybacks of up to 11.39 million shares. • Cumulative repurchases under this mandate now total 43,400 shares, equivalent to 0.038 % of issued shares at the mandate date. • A 30-day moratorium on new share issues or treasury share disposals runs until 25 June 2026.

Board confirmation The company affirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.